Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310673 · ClinicalTrials.gov registry record · Phase 4
Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
A Phase 4 study, sponsored by White River Junction Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
NCT01310673 is a Phase 4 study that has completed, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 57 participants.
The verdict
NCT01310673, a Phase 4 study, has completed, sponsored by White River Junction Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
Study Summary
Medical teaching suggests allopurinol should not be initiated in the setting of an acute attack of gout, as rapid lowering of serum urate may exacerbate the attack. This study tests the hypothesis that there is no difference in patient reported daily pain or flair occurrences with early versus delayed institution of allopurinol during an acute gout attack.
Interventions
- DRUG Placebo
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 1998-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310673
The ClinicalTrials.gov registry entry for NCT01310673 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is White River Junction Veterans Affairs Medical Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01310673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310673 about?
NCT01310673 is a clinical study titled "Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout". Medical teaching suggests allopurinol should not be initiated in the setting of an acute attack of gout, as rapid lowering of serum urate may exacerbate the attack. This study tests the hypothesis that there is no difference in patient reported daily pain or flair occurrences with early versus delay...
What is the current status of trial NCT01310673?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 1998-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT01310673?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT01310673?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.